Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group


Lead Sponsor: Institut Claudius Regaud

Source Institut Claudius Regaud
Brief Summary

The purpose of this study is to draw an "immune landscape profiling" of all SARRA (" SARcomes RAres ") subtypes in order to identify new innovative therapeutic strategies for these sarcomas. The impact of different factors (the transcriptomic signature CINSARC (Complexity Index in SARComas), the tumor infiltration of immune populations and the Cancer-Testis Antigens (CTA) expression) on tumour behaviour and clinical outcome will be studied.

More than 500 tumours will be analysed for the study.

Overall Status Not yet recruiting
Start Date September 2019
Completion Date September 2022
Primary Completion Date September 2022
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Cancer-Testis Antigens (CTA) expression 36 months for all patients
Secondary Outcome
Measure Time Frame
The rate of patients presenting high-risk CINSARC (Complexity Index in SARComas) signature 36 months for all patients
Enrollment 500

Intervention Type: Other

Intervention Name: Patient with Soft Tissue Sarcoma

Description: Tumor specimens will be collected for the study at diagnosis. Clinical data (patients and tumour characteristics) will be collected during the study for each patient included.

Arm Group Label: Patient with Soft Tissue Sarcoma



Inclusion Criteria:

1. Prospective and incident case of Soft Tissue Sarcoma (Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell neoplasm, Desmoplastic Small Round Cell Tumours, Solitary Fibrous Tumours, Alveolar Soft Part Sarcoma, Epithelioid Haemangioendothelioma, Low-Grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma)

2. Signed written informed consent

3. Patient affiliated to a Social Health Insurance in France

Exclusion Criteria:

1. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.

2. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Contact

Last Name: Thibaud VALENTIN

Phone: +33 (0)5 31 15 51 70

Email: [email protected]

Facility: Contact: Institut Universitaire du Cancer Toulouse - Oncopole Thibaud VALENTIN +33 (0)5 31 15 51 70 [email protected]
Location Countries


Verification Date

May 2019

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Patient with Soft Tissue Sarcoma

Type: Other

Acronym MIRAS
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Other

Masking: None (Open Label)